Novartis to market JE vaccine
31 March 2009 00:00 in Pharmaceutical Company Product News
Novartis will market a vaccination which could protect thousands of travellers' lives who go to Asia.
As part of a strategic alliance between the company and Intercell, Ixiaro is designed to protect against Japanese Encephalitis (JE) and has now been approved by the Food and Drug Administration (FDA).
In clinical trials, the vaccination was shown to provide a protective immune response to the mosquito-borne flaviviral infection in up to 99 per cent of subjects after two doses.
"Asia is now the second most popular travel destination globally - and travel to the region is expected to increase," remarked chief executive officer of Novartis' vaccines and diagnostics division.
"JE is spread by mosquitoes, which makes it unpredictable. Vaccination is the most effective preventive measure against the disease."
This week, the FDA approved Afinitor for patients with advanced renal cell carcinoma who have not been responsive to Sutent or Nexavar.
Robert J Motzer, principal investigator of the drugs' trial, asserted the ruling would provide a "new and useful tool" for managing the disease.
Other news stories from 31/03/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency